Ann Arbor, Michigan USA (December 16 2003) – NanoBio® Corporation will use a $3.2 million contract by the U.S. Department of Defense (DOD) to support the development of antimicrobial nanoemulsions.

The award will help fund clinical trials to confirm the safety of these nanoemulsions for human topical use. Applications of the nanoemulsion technology that are of interest to the DOD include the decontamination of infectious agents on humans and the prevention of infectious disease following a bio-terrorism attack.
"This contract validates the government's interest and commitment to our technology," stated Dr. James R. Baker, Jr., Chief Scientific Officer of NanoBio®. “The DOD funded research leverages our Phase II clinical trials for the development of commercial applications of our technology.”

NanoBio® already has in development pharmaceutical treatments for fungal, viral and bacterial infections of the skin and mucous membranes.

The first topical product, a treatment for cold sores (Herpes labialis) has been approved to begin phase II clinical trials in March of 2004. In addition, trials will begin in June for a topical treatment for nail fungus (onychomycosis). NanoBio's products have important therapeutic, safety and cost advantages over currently available treatments.

Additional longer-term products in development include treatments for genital herpes, shingles, and a broad-spectrum vaginal infection treatment that is efficacious against fungal, bacterial and parasitic infections.

NanoBio® Corporation is a biopharmaceutical company whose mission is to develop and commercialize topical and mucosal pharmaceuticals based on its patented antimicrobial nanoemulsion technology. The technology was developed at the University of Michigan Medical School. NanoBio®, a privately held corporation, is the exclusive licensee of this technology.